Business Description
Medtronic PLC
NAICS : 334510
SIC : 3845
ISIN : IE00BTN1Y115
Compare
Compare
Traded in other countries / regions
MDT.USA0Y6X.UK2M6.GermanyMDTN.MexicoMDT.Argentina1MDT.ItalyMDT.AustriaMDTC34.Brazil IPO Date
2023-11-13Description
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.5 | |||||
Debt-to-EBITDA | 3.05 | |||||
Interest Coverage | 7.69 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.72 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3 | |||||
3-Year EBITDA Growth Rate | 3.5 | |||||
3-Year EPS without NRI Growth Rate | 5.4 | |||||
3-Year FCF Growth Rate | 2.7 | |||||
3-Year Book Growth Rate | 0.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 4.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 3.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 23.98 | |||||
9-Day RSI | 31.89 | |||||
14-Day RSI | 35.91 | |||||
6-1 Month Momentum % | 1.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 1.55 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 180.03 | |||||
Days Sales Outstanding | 67.29 | |||||
Days Payable | 74.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.61 | |||||
Dividend Payout Ratio | 0.26 | |||||
3-Year Dividend Growth Rate | 6 | |||||
Forward Dividend Yield % | 3.54 | |||||
5-Year Yield-on-Cost % | 2.4 | |||||
3-Year Average Share Buyback Ratio | 0.9 | |||||
Shareholder Yield % | 5.87 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 65.35 | |||||
Operating Margin % | 17.06 | |||||
Net Margin % | 11.36 | |||||
FCF Margin % | 16.04 | |||||
ROE % | 7.18 | |||||
ROA % | 4.06 | |||||
ROIC % | 5.58 | |||||
ROC (Joel Greenblatt) % | 50.7 | |||||
ROCE % | 6.87 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 28.62 | |||||
Forward PE Ratio | 14.47 | |||||
PE Ratio without NRI | 15.11 | |||||
Shiller PE Ratio | 23.19 | |||||
Price-to-Owner-Earnings | 25.38 | |||||
PS Ratio | 3.23 | |||||
PB Ratio | 2.06 | |||||
Price-to-Free-Cash-Flow | 20.1 | |||||
Price-to-Operating-Cash-Flow | 15.41 | |||||
EV-to-EBIT | 21.24 | |||||
EV-to-Forward-EBIT | 16.59 | |||||
EV-to-EBITDA | 14.38 | |||||
EV-to-Forward-EBITDA | 13.26 | |||||
EV-to-Revenue | 3.64 | |||||
EV-to-Forward-Revenue | 3.53 | |||||
EV-to-FCF | 22.68 | |||||
Price-to-Projected-FCF | 1.15 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Earnings Yield (Greenblatt) % | 4.71 | |||||
FCF Yield % | 5.15 | |||||
Forward Rate of Return (Yacktman) % | 6.46 |